Avanir's Main Product Is Nuedexta
Avanir (NASDAQ:AVNR) is a small (~$500M market cap) pharmaceutical company that develops and sells drugs for central nervous system disorders. It has two drugs on the market, Nuedexta and Abreva, and a couple in the pipeline. In the company's most recently reported quarterly results released December 10, Nuedexta, which has a gross margin of 94.3%, accounted for 93% of Avanir's total net revenue. It grossed $91.2 million in revenue for the year, representing more than 100% growth on a year-over-year basis. Nuedexta will become even more important to Avanir this spring, as the company will stop recognizing revenue from its only other approved product, Abreva, when its patent expires in April 2014. Some...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|